<DOC>
	<DOCNO>NCT02306538</DOCNO>
	<brief_summary>Breast cancer common cancer amongst Canadian woman . 15-20 % early breast cancer high level protein call HER2 associate bad survival . Treatment patient anthracyclines follow trastuzumab ( target HER2 ) improve survival . Unfortunately , medication together cause heart muscle injury result heart dysfunction failure 14 % 3.6 % patient , respectively . Once heart failure ( HF ) occur , 60 % patient live past 2 year . Studies suggest patient heart injury cause anthracyclines may likely develop HF addition trastuzumab . Therefore test find early heart injury anthracyclines may allow doctor start heart protective medication hope prevent HF . Also , animal small patient study show increase water level heart muscle ( edema ) may early sign heart injury anthracyclines . Cardiac MRI unique technique show detect edema various heart disease . The investigator test theory , woman receive treatment breast cancer , heart edema detect MRI end anthracyclines identify patient later develop heart dysfunction . MRI study novel technique do pre-therapy , anthracyclines , herceptin , end therapy . The investigator compare patient without heart dysfunction test patient heart dysfunction likely edema anthracyclines . Ultimately investigator hope use cardiac MRI identify high risk patient study various heart protective medication prevent HF . This improve personal health cancer patient allow live free heart disease cancer therapy . Ultimately population level allow doctor provide care uniquely design patient base individual risk .</brief_summary>
	<brief_title>Evaluation Myocardial Changes During BReast Adenocarcinoma Therapy Detect Cardiotoxicity Earlier With MRI</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<criteria>Scheduled undergo treatment one follow regimen : ( ) 5fluorouracil , epirubicin , cyclophosphamide , follow docetaxel trastuzumab , ( b ) adriamycin , cyclophosphamide , follow docetaxel trastuzumab , ( c ) adriamycincyclophosphamide weekly paclitaxel trastuzumab , ( ) dose dense adriamycin cyclophosphamide follow dose dense paclitaxel trastuzumab Able tolerate four ~60 minute CMR examinations 15 month Able give inform consent Life expectancy &lt; 12 month Participating clinical trial new cancer drug Having receive previous anthracycline History myocardial infarction previous heart failure Current unstable angina , persistent atrial fibrillation irregular rhthym , history mild regurgitant stenotic valvular heart disease Severely reduce renal function ( GFR â‰¤ 30mL/min ) General MRI contraindication Baseline LVEF &lt; 55 % echo echocardiography image quality inadequate strain analysis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>edema</keyword>
	<keyword>inflammation</keyword>
	<keyword>scar</keyword>
	<keyword>ejection fraction</keyword>
	<keyword>volume</keyword>
</DOC>